---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-21-000431"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2021-10-19T23:59:59+00:00"
generated_at: "2026-06-28T19:59:21.126970+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma engages Biotech Research Group for NR2F6 IP assessment at $25k total

## Summary
- Engaged BRG to perform a GAP assessment of CRO work on NR2F6 checkpoint pre-clinical protocols, raw data, and completion report.
- Total fee of $25,000 due immediately upon SOW signing; work to be completed by November 15, 2021.
- Deliverables include a gap assessment report and a regulatory strategy work package for NR2F6 IP.
- Scope of Work Order effective October 11, 2021, under existing Master Services Agreement dated May 12, 2021.

## SEC filing metadata
- accession: 0001607062-21-000431
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2021-10-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000431/0001607062-21-000431-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000431/rgbp101821form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-21-000431
- JSON: https://secwatch.observer/filing/0001607062-21-000431.json
- Plain text: https://secwatch.observer/filing/0001607062-21-000431.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.